53rd Annual Award Recipient
Michael R. Stratton, Ph.D.
Director, The Wellcome Trust Sanger Institute
Wellcome Trust Sanger Institute
Dr. Stratton delivered his award lecture titled The Causes of Mutations in Human Cancer
, at the AACR Annual Meeting 2013 in Washington, D.C. The award ceremony and lecture was held on Monday, April 8, 2013. Visit the AACR Annual Meeting 2013
page for more information on the Annual Meeting.
The Award and Lecture
AACR and Eli Lilly and Company established this award in 1961 to honor Dr. G.H.A. Clowes, who was a founding member of the AACR and a research director of Eli Lilly. The Clowes Award recognizes an individual with outstanding recent accomplishments in basic cancer research.
The winner of the 53rd Annual AACR G.H.A. Clowes Memorial Award received a $10,000 honorarium, gave a 50-minute lecture during the AACR Annual Meeting 2013 in Washington, DC, USA (April 6-10, 2013), and was given support for the winner and a spouse to attend the Annual Meeting. The winner will also speak at the Eli Lilly and Company headquarters in Indianapolis, Indiana, at the invitation of the company later in 2013.
- Candidacy is open to all cancer researchers who are affiliated with any institution involved in cancer research, cancer medicine or cancer-related biomedical science anywhere in the world. Such institutions include those in academia, industry or government.
- The award will be presented to an individual investigator.
- Institutions or organizations are not eligible for the award.
Nomination Procedure and Instructions
Nominations are closed.
Nominations may be made by any scientist, whether an AACR member or nonmember, who is now or has been affiliated with any institution involved in cancer research, cancer medicine or cancer-related biomedical science. Candidates may not nominate themselves.
Candidates will be considered by a committee of international cancer leaders appointed by the president of the AACR. After careful deliberations by the Award Committee, its recommendations will be forwarded to the Executive Committee of the AACR for final consideration and decision. Selection of the award winner will be made on the basis of the candidate’s recent accomplishments in basic cancer research. No regard will be given to age, race, gender, nationality, geographic location or religious or political views.
Generously supported by Eli Lilly and Company.
Linda Stokes, Program Associate
American Association for Cancer Research
17th Floor, 615 Chestnut Street
Philadelphia, PA 19106-4404
52nd Annual Recipient
Alan D. D'Andrea, M.D.
Alvan T. and Viola D. Fuller
American Cancer Society
Professor of Radiation Oncology
Harvard Medical School
Scientific Director, Molecular Diagnostics Laboratory
Dana-Farber Cancer Institute
Dr. Alan D. D'Andrea (center) delivered his award lecture entitled, Targeting DNA Repair in Cancer Therapy: Lessons from Fanconi Anemia, during the AACR Annual Meeting 2012 in Chicago, IL. Dr. D'Andrea received his award from Selection Committee member, Dr. Myles Brown (left) and Eli Lilly Representative, Dr. Greg Plowman (right).
Dr. Alan D. D’Andrea’s scientific notoriety began when he cloned the erythropoietin (EPO) receptor during his postdoctoral studies in Harvey Lodish’s laboratory. We now understand that this receptor is one of the vital proteins that regulate red blood cell production (angiogenesis) and survival. The ability of this protein to govern angiogenesis, a process essential to cancer survival, has rendered it an attractive target for cancer therapeutics. Dr. D’Andrea’s continued work involving the EPO receptor is centered around understanding how point mutations and epigenetic modifications of the receptor alter downstream intracellular signaling pathways including the JAK/STAT (Janus Kinase/Signal Transducer and Activator of Transcription) and MAPK (Mitogen-Activated Protein Kinase) signaling pathways within hematological malignancies.
In addition to his work regarding the EPO receptor, Dr. D’Andrea has contributed immensely to our understanding of DNA damage and its effects on chromosomal stability, cell cycle progression and cancer susceptibility. His research has centered on investigating these processes within rare chromosomal instability syndromes including ataxia telangiectasia, Bloom’s syndrome, and most extensively, Fanconi anemia, which often results in the onset of acute myelogenous leukemia.
In his pursuit to understand DNA repair mechanisms, Dr. D’Andrea initially discovered the Fanconi anemia protein (FANCC; Fanconi Anemia Complementation Group C) involved in the maintenance of chromosomal stability. He later discovered that this protein is one of several that comprise a complex that blocks the deleterious effects of DNA crosslinking agents and maintains chromosomal integrity. His research has since identified that members of the Fanconi anemia family of proteins are subject to post-translational modifications that promote their interaction with DNA repair proteins such as ATM (ataxia telangiectasia) and BRCA1 (breast cancer 1, early onset) prior to their recruitment to sites of chromosomal damage. At the time, this was the first evidence to suggest that DNA repair systems cooperated with chromosomal stability mechanisms within cells.
Subsequent studies demonstrated that not only are Fanconi anemia proteins directly linked to DNA repair mechanisms in the cell, but one such member, FANCD1 is identical to the previously identified breast cancer tumor suppressor gene involved in double-strand DNA break repair, BRCA2. Collectively, these findings are absolutely vital to our continued understanding of cancer progression and survival and have significantly altered our knowledge of DNA instability and repair mechanisms and have showcased the biological relationships present between rare hereditary diseases such as Fanconi anemia and cancer.
Dr. D’Andrea received his M.D. from Harvard Medical School. Afterward, he performed his residency at The Children’s Hospital of Philadelphia within the field of pediatrics and his fellowship back in Boston within the Dana-Farber Cancer Institute and Children’s Hospital of Boston where he concentrated on pediatric hematology and oncology. Later, he conducted his postdoctoral studies at the Whitehead Institute until he returned to the Dana-Farber Cancer Institute and Children’s Hospital of Boston where he has remained, currently serving as the Alvan T. and Viola D. Fuller American Cancer Society professor of radiation oncology, scientific director of the Molecular Diagnostics Laboratory, and director of the Clinical Gene Therapy Center. He has received numerous awards for his research accomplishments including the American Academy of Pediatrics Excellence in Research Award, the E. Mead Johnson Award for Research in Pediatrics, and the Fanconi Anemia Scientific Symposium’s Award of Merit, along with publishing a multitude of papers in high-tiered journals that have been heavily cited for their content.